The US Food and Drug Administration has granted a “breakthrough therapy” designation to a formulation of LSD shown to treat generalized anxiety disorder. The decision was based on clinical trials that showed the drug “exhibited rapid and robust efficacy” in reducing anxiety, “solidly sustained for 12 weeks after a single dose.” — Read the rest
The post One LSD trip shown to provide rapid and lasting reduction in anxiety, FDA designates "breakthrough therapy" appeared first on Boing Boing.
